Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
67,623.29 +376.42 (+0.56%) CMC Crypto 200
1,423.46 -5.11 (-0.36%)
SLNO Dec 2024 30.000 put
| Previous close | 3.9000 |
| Open | 3.9000 |
| Bid | 1.5000 |
| Ask | 5.2000 |
| Strike | 30.00 |
| Expiry date | 2024-12-20 |
| Day's range | 3.9000 - 3.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
GlobeNewswireSoleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4,
- GlobeNewswire
Soleno Therapeutics to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Event: Jefferies Global Healthcare ConferenceDay: Wednesday, June 5, 2024Time:11:30 AM Eastern Time Event:Goldman Sachs 45th Annual Global Healthcare
- GlobeNewswire
Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi syndrome communityREDWOOD CITY, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today launched a groundbreaking initiative in honor of Prader-Willi Syndrome (PWS) Awareness Day. The campaign
